Getting It Right First Time (GIRFT): what every NHS board should know
18 August 2026
Andrew Corbett-Nolan traces the origins of GIRFT and highlights its importance to clinical governance
Points raised in this article
- GIRFT makes clinical effectiveness measurable, comparative and clinician-led
- Strong governance turns GIRFT recommendations into sustained improvement
- Quality-led variation reduction improves outcomes, capacity and productivity
- Boards must embed GIRFT within core clinical governance
Clinical governance has been a cornerstone of NHS accountability for more than a quarter of a century. First formalised in the wake of the Bristol heart scandal and reinforced by every major inquiry since (Shipman, Francis, Ockenden and beyond), it is defined as ‘a framework through which NHS organisations are accountable for continually improving the quality of their services and safeguarding high standards of care by creating an environment in which excellence in clinical care will flourish.’ At its heart lie three interlocking domains: patient safety, clinical effectiveness and patient experience.
Of these, clinical effectiveness has too often been the quietest sibling. Safety generates the headlines and the serious incident reports. Experience is measured through surveys and complaints. Clinical effectiveness – doing the right thing, in the right way, for the right patient, at the right time and proving that outcomes are improving – can feel more diffuse, more technical and easier to relegate to the clinical audit schedule. Yet without robust clinical effectiveness, the other two pillars rest on shaky ground.
Enter Getting It Right First Time (GIRFT). What began as a single orthopaedic surgeon’s determination to confront unwarranted variation has become one of the most significant practical expressions of clinical effectiveness in the modern NHS. It is not another national programme to be endured. Properly understood and properly governed, GIRFT is clinical governance in action at its best.
The origins of this simple but powerful idea
The story begins in 2012. Professor Tim Briggs, then president of the British Orthopaedic Association and a consultant at the Royal National Orthopaedic Hospital, secured modest funding for a pilot review of elective orthopaedic surgery across England. Armed with data from multiple sources and a willingness to visit every unit in the country, he exposed striking variation in practice, outcomes, length of stay, implant choice and cost. The early results were striking: an estimated £30–50 million in efficiencies within 12 months, largely through reduced length of stay and smarter procurement, achieved without radical reorganisation or additional investment.
The first formal national report in 2015, the subsequent endorsement in Lord Carter’s review of operational productivity and substantial national investment turned a specialty pilot into a programme spanning more than 40 surgical and medical workstreams plus cross-cutting themes.
Today GIRFT sits firmly within NHS England. In November 2025 its reach expanded further when several improvement teams were unified under the GIRFT brand, bringing elective recovery, urgent and emergency care and mental health into a more coherent, clinically led improvement architecture.
The core methodology has remained consistent: rigorous data analysis producing specialty-specific packs, peer-to-peer review by practising senior clinicians, national reports and academy best-practice resources, and structured support for implementation. The language has evolved from ‘deep dives’ to peer reviews and system-level gateway reviews, but the principle is unchanged. Unwarranted variation is the enemy of both quality and value. Confront it openly, with clinicians in the room, and both improve.
GIRFT as clinical effectiveness made operational
Clinical effectiveness is more than the existence of guidelines. It is the systematic translation of evidence into consistent practice, the measurement of outcomes and the continuous reduction of unjustified differences in care. GIRFT operationalises this at scale.
It does so by creating a closed improvement loop that few other mechanisms match. Data packs place a trust’s performance in national context across dozens of metrics. Peer review turns those numbers into a conversation between clinicians who understand the realities of the specialty. Action plans convert insight into ownership. Ongoing monitoring through the Model Health System and local tracking shows whether the gap is closing. The result is not passive compliance with NICE guidance or intermittent local audits; it is active, comparative and crucially clinician-led effectiveness.
This is why GIRFT belongs at the centre of any serious clinical governance system. It strengthens the effectiveness domain directly while contributing materially to the others. Many of its recommendations reduce harm: fewer infections, fewer readmissions, fewer never events, lower litigation. Shorter stays, higher day-case rates and more reliable pathways improve experience. The data itself becomes a powerful information asset for boards. Peer review and academy resources support education and a learning culture.
In short, a mature GIRFT programme is not an add-on to clinical governance; it is one of the clearest contemporary demonstrations of clinical governance working as intended.
National and trust-level organisation
Nationally, GIRFT is organised around three core capabilities: a clinical review unit that generates the evidence and runs the reviews, an implementation and delivery function that supports change on the ground, and the GIRFT academy that codifies and spreads best practice. Specialty clinical leads (frontline experts) remain the programme’s greatest asset. Their credibility is what turns data into dialogue rather than diktat.
At trust level the picture is more variable, and this is where governance becomes decisive. The November 2024 Practical Guide to GIRFT Governance and its accompanying standard operating procedure set out a clear blueprint. The essential ingredients are:
- visible executive sponsorship, ideally the chief executive or medical director as champion
- a dedicated trust-level GIRFT team, usually linked to the medical director’s office, with capacity to co-ordinate; maintain a single repository of packs, notes and action plans; and act as the organisational memory
- specialty-level multi-professional ownership of metrics and actions
- structured preparation for and follow-up after peer or gateway reviews
- routine upward reporting from specialty and divisional governance into the quality or clinical governance committee and, ultimately, the board.
Where these elements are present, GIRFT becomes business as usual. Where they are absent, it remains a series of interesting but transient visits whose recommendations gather dust.
The cost improvement dimension
'Quality and value as two sides of the same coin' is a nice soundbite, but in a culture of cuts, clinicians can get understandably cynical. Trust CIPs are increasingly taking a GIRFT lens. Accordingly, no discussion of GIRFT is complete without addressing its contribution to cost improvement. The orthopaedic follow-up report estimated that trusts had released £696 million in operational and financial opportunities over five years through reduced length of stay, avoided low-value activity, fewer complications and better procurement. Individual specialty reports continue to quantify notional financial opportunities. Finance teams increasingly use GIRFT metrics alongside PLICS and Model Health System data when identifying CIP headroom.
Yet here lies a critical governance truth. GIRFT delivers sustainable efficiency precisely because it is quality-led. When clinicians reduce variation that has no clinical justification, capacity is released and costs fall as a consequence, not as the primary objective. Treat GIRFT as just another CIP vehicle, and clinical engagement evaporates. Treat it as a clinical effectiveness programme that also happens to be one of the most powerful productivity tools available and both quality and the bottom line benefit. Boards that understand this distinction will get far more from the programme than those that do not.
What boards and quality committees need to know and do
The quality or clinical governance committee sits at the apex of the board’s assurance system on quality. Its task is to triangulate evidence across safety, effectiveness and experience and give the board credible assurance or clear escalation. GIRFT should feature prominently in that work, not as a parallel report but as core intelligence on clinical effectiveness.
In practice, this means:
- regular, concise reporting of progress against GIRFT action plans, with RAG ratings, clinical outcome trends and quantified capacity or financial impact
- expectation that specialty clinical governance meetings review relevant GIRFT metrics alongside local audit, incidents and complaints
- inclusion of significant or persistent GIRFT outliers on the corporate risk register
- dual visibility of quality and productivity benefits so that the committee can see the full contribution
- an annual review of cross-cutting themes (coding, theatres, outpatients, litigation, procurement) that cut across individual specialties.
A mature quality committee does not drown in process papers. It receives exception-based reporting and focuses discussion on trajectory: are outcomes improving? Is variation reducing? Are we on a path to be better next year than this? GIRFT data, properly presented, is exactly the kind of comparative, outcome-orientated intelligence that enables this shift from process overload to genuine assurance.
There is also a relationship with the NHS Oversight Framework. GIRFT is explicitly part of the national improvement support offer. Strong engagement and delivery can contribute positively to a trust’s segmentation; persistent, unaddressed variation may feature in regional conversations. GIRFT performance also informs the clinical services theme within CQC ‘Use of Resources’ assessments. Boards that treat GIRFT seriously are, in effect, strengthening their position across multiple external assurance frameworks.
The system and ICB perspectives
As integrated care boards (ICBs) mature in their role as strategic commissioners, GIRFT becomes still more relevant. System-level gateway reviews bring providers and ICB colleagues into the same conversation. The data reveals variation not just within organisations but across the system. Best-practice pathways support equity of access and outcomes for the population. Capacity released in one place can be used to the benefit of the whole system. For ICBs seeking to move from transactional contracting to value-based strategic commissioning, GIRFT offers a clinically credible, evidence-rich foundation.
From insight to impact: the governance test
GIRFT’s greatest risk is not resistance; it is polite engagement without delivery. Data packs are received, peer reviews are attended, action plans are written, and then the organisational attention moves on. The difference between a programme that transforms and one that merely informs lies in governance.
A vibrant GIRFT programme needs to be supported by executive ownership that is visible and sustained. It has a central co-ordinating function with real capacity. It has specialty teams that own their metrics. It has a clear line of sight from the front line through divisional governance to the quality committee and the board. It tracks both clinical outcomes and the associated productivity benefits. It treats recommendations as commitments, not suggestions. Critically, it regards the reduction of unwarranted variation not as a technical exercise but as a core expression of the organisation’s duty of quality.
Clinical governance was never meant to be an assurance exercise. It was meant to embed a culture of continuous learning and accountability in which excellence can flourish. GIRFT, at its best, is one of the most practical tools we have for making that ambition real. It takes the abstract principle of clinical effectiveness and turns it into comparative data, peer conversation, owned action and measurable improvement.
For boards and quality committees the message is straightforward. GIRFT is not an optional extracurricular activity; it is clinical effectiveness made visible and actionable. Govern it with the same seriousness you apply to safety and experience, and you will strengthen all three pillars of clinical governance at once. Neglect its governance, and you will have another well-intentioned national programme whose potential remains largely unrealised.
The opportunity is clear. The methodology is proven. The data is richer than ever. What remains is the quality of the local governance response. That, ultimately, is a matter for boards.